This project aims to investigate the independent and combined effects of metabolic dysfunction-associated steatotic liver disease (MASLD) and underlying comorbidities on adverse clinical outcomes.
1) Research Questions
Does MASLD independently increase the risk of cardiovascular events, chronic kidney disease progression, and mortality?
How do underlying comorbidities such as cardiovascular disease, diabetes, and chronic kidney disease interact with MASLD to influence these risks?
Can specific comorbidity patterns identify high-risk MASLD subgroups for targeted screening and intervention?
2) Objectives
To quantify the independent association between MASLD and major adverse clinical outcomes.
To evaluate the synergistic effects of MASLD and common comorbidities on disease progression and mortality.
To develop a comorbidity-based risk stratification model to guide early detection and integrated care strategies.
3) Scientific Rationale
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem disorder with metabolic and inflammatory pathways overlapping those of cardiovascular and renal diseases. However, the degree to which coexisting conditions modify MASLD-associated risks remains unclear. Understanding these interactions is essential for developing effective prevention strategies, refining clinical decision-making, and optimizing healthcare resource allocation.
– Med. 2024 Nov 8;5(11):1413-1423.e3. doi: 10.1016/j.medj.2024.07.013. Epub 2024 Aug 7.
– Front Cell Dev Biol. 2024 Jul 16:12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
– Commun Med (Lond). 2025 Apr 16;5(1):118. doi: 10.1038/s43856-025-00821-x.